bluebird bio price target raised to $58 from $51 at Piper Jaffray Piper Jaffray raised its price target for bluebird bio (BLUE) shares to $58 saying the beta thal market provides opportunity for both bluebird and Biogen (BIIB). Piper sees a possible market split should both companies' data remain positive. It keeps an Overweight rating on bluebird bio.
bluebird bio price target raised to $119 from $112 at Piper Jaffray Piper Jaffray raised its price target for bluebird bio to $119 following the company's Q4 results and reiterates an Overweight rating on the name. Piper sees 2015 as a "big year" for bluebird with preliminary sickle cell data.